Logo Image
News
Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference Coverage Conference Listing
Events
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
More
Resources
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Resources
  • Subscribe
  • Blood Cancers
    • MPN
    • MDS
    • Myeloma
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Childhood Cancers
  • Gastrointestinal Cancers
    • Colorectal Cancer
    • Esophageal Cancer
    • Gastrointestinal stromal tumor
    • Liver Cancer
    • Pancreatic Cancer
  • Genitourinary Cancers
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
  • Gynecologic Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head & Neck Cancer
  • Leukemia
    • Acute Lymphoblastic Leukemia
    • Acute Myeloid Leukemia
    • CLL
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
  • Lymphoma
    • Follicular Lymphoma
    • Mantle Cell Lymphoma
    • Non-Hodgkin Lymphoma
  • Rare Cancers
    • Neuroendocrine Cancer
  • Sarcoma
  • Skin Cancer
    • Advanced Melanoma
  • Thyroid Cancer
Spotlight -
Blogs|
Breast Cancer Webinar Series|
Cancer Horizons|
Clinical Trial Corner|
Heal®|
Publications|
Videos
Advertisement

Timothy Burns

Advertisement

Articles by Timothy Burns

Out of Several Recent Drug Approvals in NSCLC, Tabrecta Most 'Practice Changing' of All, According to Expert

ByRyan McDonald,Timothy Burns
July 13th 2020

“One FDA approval that we were quite excited about (is Tabrecta). And I've actually already put some patients on it; it's a very good drug,” Dr. Timothy Burns said in a recent interview.

Advertisement

Latest Updated Articles

  • Out of Several Recent Drug Approvals in NSCLC, Tabrecta Most 'Practice Changing' of All, According to Expert
    Out of Several Recent Drug Approvals in NSCLC, Tabrecta Most 'Practice Changing' of All, According to Expert

    July 13th 2020



Advertisement
Advertisement

Trending on CURE

1

Precision Radiation Cuts 1-Year Pancreatic Cancer Recurrence to 20.2%

2

3 Prostate Cancer Results From ESMO 2026 Patients Should Know

3

The Breast Cancer Test Many Patients Don’t Know to Ask For

4

5 Years of Pancreatic Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients

5

Urologic Oncologist Answers Top Searched Questions in Bladder Cancer

  • About Us
  • Advertise / Support
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • TargetedOnc.com
  • OncLive.com
  • OncNursingNews.com
  • Terms & Conditions
  • Privacy
  • Do Not Sell My Information
  • Washington My Health My Data
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.